Company News

MetaStat Appoints Jerome B. Zeldis, M.D., Ph.D. to its Board of Directors

Download PDF

Experienced Drug Developer Joins MetaStat’s Board of Directors as Vice Chairman

BOSTON-- MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company, today announced the appointment of Jerome B. Zeldis, M.D., Ph.D. to serve as Vice Chairman of the company’s Board of Directors. Dr. Zeldis is the Chief Medical Officer of Celgene Corporation (NASDAQ: CELG) and Chief Executive Officer of Celgene Global Health.

“We are delighted to have Dr. Zeldis join the MetaStat team,” said Douglas A. Hamilton, President and Chief Executive Officer, MetaStat, Inc. “I look forward to working with Jerry to broaden our diagnostic opportunities in oncology while monetizing our novel therapeutic assets, including potential drug candidates that target selected drivers of cancer metastasis.”

Dr. Zeldis is the Chief Medical Officer of Celgene Corporation and Chief Executive Officer of Celgene Global Health. Prior to joining Celgene in 1997, Dr. Zeldis held positions at Sandoz Research Institute and Janssen Research Institute in both clinical research and medical development. He currently serves as Chairman of the board of Alliqua and Trek Therapeutics in addition to board positions at Bionor Pharma, PTC Therapeutics, and Soligenix. He was Assistant Professor of Medicine at Harvard Medical School, Associate Professor of Medicine at University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School, and Professor of Clinical Medicine at the Robert Wood Johnson Medical School. Dr. Zeldis received BA and MS degrees from Brown University, and M Phil, MD, and PhD degrees from Yale University. Dr. Zeldis has published 121 peer-reviewed articles and 24 reviews, as well as a number of book chapters, and editorials.

“MetaStat’s exciting technology based on the mechanisms that drive cancer metastasis, create the potential for next generation cancer diagnostics and an opportunity to develop novel cancer drugs in conjunction with strategic partners” stated Dr. Zeldis. “I look forward to helping expand development of MetaStat’s unique technology by creating new opportunities for these proprietary biomarkers for solid tumor metastasis.”

About MetaStat, Inc.

MetaStat develops and commercializes tissue-based diagnostic tests for prediction of cancer metastasis. MetaStat is focused on epithelial-based cancers including breast, lung, prostate and colorectal. MetaStat's driver-based diagnostic platform technology is based on the pivotal role of the Mena protein and its isoforms, a common pathway for the development of metastatic disease in epithelial-based solid tumors. Our MetaSite Breast™ and MenaCalc™ assays are designed to accurately stratify patients based on the aggressiveness of their tumor and risk the cancer will spread. MetaStat's testing platform improves treatment planning decisions by positively identifying patients at high-risk of metastasis who need aggressive therapy and by sparing low-risk patients from the harmful side effects and expense of adjuvant chemotherapy.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the company undertakes no obligation to update such statements.

For MetaStat, Inc.:
Rick Pierce, 617-531-0874

Source: MetaStat, Inc.